- Ionis Pharmaceuticals (IONS) Wednesday reported that it has entered into a license agreement with Recordati, under which Recordati obtained exclusive rights to develop and commercialize zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), in all countries outside the U.S.
- Ionis will
